The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II open-label, single-center study evaluating safety and efficacy of pembrolizumab following induction with the hypomethylating agent azacitidine in patients with advanced pancreatic cancer after failure of first-line therapy.
 
Rachael A Safyan
No Relationships to Disclose
 
Tamas Gonda
No Relationships to Disclose
 
Benjamin Tycko
No Relationships to Disclose
 
John A. Chabot
No Relationships to Disclose
 
Gulam Abbas Manji
No Relationships to Disclose
 
Gary K. Schwartz
Honoraria - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics
Consulting or Advisory Role - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology)
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Paul Eliezer Oberstein
Consulting or Advisory Role - Merck; Purdue Pharma; Purdue Pharma
Research Funding - Aduro Biotech (Inst); Celgene (Inst); Halozyme (Inst); Merck (Inst); Roche/Genentech (Inst)